Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Ralph H. Hruban

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4554-5672; OpenAlex author ID A5001682484; NIH RePORTER profile ID 2158423. Sources: OpenAlex.

Their work

Papers
168 (first author 4, last author 10)
Trials
0
Grants
1
Labs led
1
Collaborators
443
Papers, trials and grants by year

2011: 10 papers · 2012: 12 papers · 2013: 12 papers · 2014: 5 papers · 2015: 13 papers · 2016: 11 papers · 2017: 14 papers · 2018: 11 papers · 2019: 17 papers · 2020: 16 papers · 2021: 12 papers · 2022: 10 papers, 1 grant · 2023: 6 papers · 2024: 8 papers · 2025: 4 papers · 2026: 7 papers

Papers 50 of 168

  1. Quantitative 3D histology reveals localized immune remodeling during early pancreatic cancer progression. Co-author DOI 10.1016/j.cpblue.2026.100008↗
  2. Metastatic pancreatic acinar cell carcinoma to the liver mimicking neuroendocrine tumor (NET) and pancreatic ductal adenocarcinoma (PDAC): A series of seven ca… First author DOI 10.1016/j.humpath.2026.106213↗
  3. The Long, Remarkable History of KRAS and Pancreatic Cancer: From Gene Discovery to Successful Therapeutic Targeting. Co-author DOI 10.1016/j.modpat.2026.101059↗
  4. High-Sensitive Spatial Proteomics for Pancreatic Cancer Progression Analysis. Co-author DOI 10.1021/acs.analchem.5c01928↗
  5. Integrated driver gene-based survival prediction in resected pancreatic cancer. Co-author DOI 10.1093/bjs/znag123↗
  6. Incidental Diagnosis of Pancreatic Cancer and Association with Improved Patient Outcomes: Assessing the Potential Clinical Use of Liquid Biopsy-Based Screening… Co-author DOI 10.1097/xcs.0000000000001721↗
  7. Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer. Co-author DOI 10.1172/jci190121↗
  8. Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to Pancreatic Cancer in High-Risk Individuals. Co-author DOI 10.1016/j.gastha.2025.100802↗
  9. Reversible chemoresistance of pancreatic cancer grown as spheroids. Co-author DOI 10.1080/1120009x.2024.2402177↗
  10. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794↗
  11. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  12. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  13. Hidden in plain sight: commonly missed early signs of pancreatic cancer on CT. Co-author DOI 10.1007/s00261-024-04334-4↗
  14. Early detection of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1007/s00261-024-04358-w↗
  15. Precursor lesions in familial and hereditary pancreatic cancer. Last author DOI 10.1007/s10689-024-00359-2↗
  16. Detection of Pancreatic Ductal Adenocarcinoma-Associated Proteins in Serum. Co-author DOI 10.1016/j.mcpro.2023.100687↗
  17. Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002326↗
  18. Power-law growth models explain incidences and sizes of pancreatic cancer precursor lesions and confirm spatial genomic findings. Co-author DOI 10.1126/sciadv.ado5103↗
  19. A mucus production programme promotes classical pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2023-329839↗
  20. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Co-author DOI 10.1002/jhbp.1303↗
  21. Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer. Last author DOI 10.1016/j.medj.2022.11.009↗
  22. Screening for pancreatic cancer has the potential to save lives, but is it practical? Last author DOI 10.1080/17474124.2023.2217354↗
  23. Radiologists' Expectations of Artificial Intelligence in Pancreatic Cancer Imaging: How Good Is Good Enough? Co-author DOI 10.1097/rct.0000000000001503↗
  24. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  25. Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer. Co-author DOI 10.1111/his.14839↗
  26. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. Co-author DOI 10.1002/ijc.33883↗
  27. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-021-06410-y↗
  28. CODA: quantitative 3D reconstruction of large tissues at cellular resolution Co-author DOI 10.1038/s41592-022-01650-9↗
  29. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  30. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  31. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
  32. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  33. Neoplastic cell enrichment of tumor tissues using coring and laser microdissection for proteomic and genomic analyses of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12014-022-09373-x↗
  34. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  35. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  36. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
  37. Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s00268-021-06209-x↗
  38. Pancreatic cancer pathology viewed in the light of evolution. Last author DOI 10.1007/s10555-020-09953-z↗
  39. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  40. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.cell.2021.08.023↗
  41. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.03.015↗
  42. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  43. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
  44. Pancreatic Cancer Imaging: A New Look at an Old Problem. Co-author DOI 10.1067/j.cpradiol.2020.08.002↗
  45. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001888↗
  46. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  47. CT Radiomics-Based Preoperative Survival Prediction in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.20.23490↗
  48. Pitfalls in the MDCT of pancreatic cancer: strategies for minimizing errors. Co-author DOI 10.1007/s00261-019-02390-9↗
  49. Diagnostic performance of commercially available vs. in-house radiomics software in classification of CT images from patients with pancreatic ductal adenocarci… Co-author DOI 10.1007/s00261-020-02556-w↗
  50. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗

Grants 1

  1. Core 2: Biospecimen/Pathology Core P50CA062924↗

Closest collaborators

The 25 strongest of 443 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Goggins · 53 shared papers, 1 shared grant, 2011–2025 · strength 4.18
  2. Jin Peng He · 41 shared papers, 2013–2026 · strength 4.10
  3. Elliot K. Fishman · 38 shared papers, 2012–2026 · strength 3.80
  4. Christopher Lee Wolfgang · 57 shared papers, 2011–2025 · strength 3.50
  5. Alison P. Klein · 35 shared papers, 1 shared grant, 2011–2024 · strength 3.07
  6. Laura DeLong Wood · 30 shared papers, 2013–2026 · strength 2.68
  7. Richard Andrew Burkhart · 20 shared papers, 2018–2026 · strength 2.39
  8. Matthew John Weiss · 27 shared papers, 2015–2023 · strength 2.04
  9. Nicholas Jason Roberts · 20 shared papers, 2012–2026 · strength 2.03
  10. Daniel A. Laheru · 31 shared papers, 2011–2023 · strength 2.01
  11. Linda Chi Hang Chu · 13 shared papers, 2019–2025 · strength 1.96
  12. Ammar A. Javed · 14 shared papers, 2018–2026 · strength 1.91
  13. Marcia Irene Canto · 21 shared papers, 2012–2025 · strength 1.85
  14. Satomi Kawamoto · 11 shared papers, 2019–2024 · strength 1.55
  15. Anne Marie Lennon · 14 shared papers, 1 shared grant, 2013–2024 · strength 1.52
  16. Joseph M. Herman · 34 shared papers, 2011–2022 · strength 1.52
  17. James R. Eshleman · 17 shared papers, 2011–2026 · strength 1.44
  18. Amanda L. Blackford · 15 shared papers, 2012–2025 · strength 1.37
  19. Lei Zheng · 20 shared papers, 2012–2022 · strength 1.29
  20. Jun Yu · 18 shared papers, 2012–2023 · strength 1.26
  21. Amol Kumar Narang · 15 shared papers, 2012–2022 · strength 1.20
  22. Kelly J. Lafaro · 7 shared papers, 2021–2026 · strength 1.11
  23. Scott E Kern · 2 shared papers, 1 shared grant, 2021–2026 · strength 1.03
  24. Denis Wirtz · 6 shared papers, 2017–2026 · strength 0.99
  25. Bert Vogelstein · 11 shared papers, 1 shared grant, 2012–2023 · strength 0.97

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.